Published in J Am Coll Cardiol on March 21, 2013
Pharmacogenetics of heart failure. Curr Opin Cardiol (2014) 0.75
Inherited Arrhythmias - Where do we Stand? Arrhythm Electrophysiol Rev (2014) 0.75
Initial sequencing and analysis of the human genome. Nature (2001) 212.86
A haplotype map of the human genome. Nature (2005) 105.70
Finding the missing heritability of complex diseases. Nature (2009) 67.95
An integrated encyclopedia of DNA elements in the human genome. Nature (2012) 64.73
Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proc Natl Acad Sci U S A (2009) 54.68
The diploid genome sequence of an individual human. PLoS Biol (2007) 44.80
Common SNPs explain a large proportion of the heritability for human height. Nat Genet (2010) 35.02
Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med (1995) 28.35
Prospects for whole-genome linkage disequilibrium mapping of common disease genes. Nat Genet (1999) 25.93
Relative impact of nucleotide and copy number variation on gene expression phenotypes. Science (2007) 23.38
A common allele on chromosome 9 associated with coronary heart disease. Science (2007) 20.37
A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science (2007) 18.96
Evolution and functional impact of rare coding variation from deep sequencing of human exomes. Science (2012) 17.12
Five years of GWAS discovery. Am J Hum Genet (2012) 12.97
SLCO1B1 variants and statin-induced myopathy--a genomewide study. N Engl J Med (2008) 11.31
The mystery of missing heritability: Genetic interactions create phantom heritability. Proc Natl Acad Sci U S A (2012) 11.23
Online Mendelian Inheritance in Man (OMIM), a knowledgebase of human genes and genetic disorders. Nucleic Acids Res (2002) 9.50
Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med (2008) 9.25
The eMERGE Network: a consortium of biorepositories linked to electronic medical records data for conducting genomic studies. BMC Med Genomics (2011) 9.20
The case for cloud computing in genome informatics. Genome Biol (2010) 9.20
Estimation of significance thresholds for genomewide association scans. Genet Epidemiol (2008) 8.88
Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med (2012) 8.24
An abundance of rare functional variants in 202 drug target genes sequenced in 14,002 people. Science (2012) 7.94
Variation is the spice of life. Nat Genet (2001) 7.62
Genetic variation in an individual human exome. PLoS Genet (2008) 6.68
An atlas of combinatorial transcriptional regulation in mouse and man. Cell (2010) 6.24
Truncations of titin causing dilated cardiomyopathy. N Engl J Med (2012) 6.07
A molecular basis for familial hypertrophic cardiomyopathy: a beta cardiac myosin heavy chain gene missense mutation. Cell (1990) 5.77
The eukaryotic genome as an RNA machine. Science (2008) 5.29
Identification of a gene responsible for familial Wolff-Parkinson-White syndrome. N Engl J Med (2001) 4.46
Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial. Lancet (2012) 4.36
Exome sequencing and the genetic basis of complex traits. Nat Genet (2012) 4.11
Mutations in SMAD3 cause a syndromic form of aortic aneurysms and dissections with early-onset osteoarthritis. Nat Genet (2011) 3.93
Accurate whole-genome sequencing and haplotyping from 10 to 20 human cells. Nature (2012) 3.74
Comprehensive identification and characterization of diallelic insertion-deletion polymorphisms in 330 human candidate genes. Hum Mol Genet (2004) 3.73
Integrating pathway analysis and genetics of gene expression for genome-wide association studies. Am J Hum Genet (2010) 3.63
A randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin dosing (CoumaGen-II). Circulation (2012) 3.30
Design of the Coronary ARtery DIsease Genome-Wide Replication And Meta-Analysis (CARDIoGRAM) Study: A Genome-wide association meta-analysis involving more than 22 000 cases and 60 000 controls. Circ Cardiovasc Genet (2010) 3.15
Expression of the familial hypercholesterolemia gene in heterozygotes: mechanism for a dominant disorder in man. Science (1974) 3.05
Targeted next-generation sequencing for the molecular genetic diagnostics of cardiomyopathies. Circ Cardiovasc Genet (2011) 2.45
Genome-wide studies of copy number variation and exome sequencing identify rare variants in BAG3 as a cause of dilated cardiomyopathy. Am J Hum Genet (2011) 2.38
Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma. Nat Genet (2011) 2.29
A transgenic rabbit model for human hypertrophic cardiomyopathy. J Clin Invest (1999) 2.19
Leveraging models of cell regulation and GWAS data in integrative network-based association studies. Nat Genet (2012) 2.02
Medicine. Whole-genome sequencing: the new standard of care? Science (2012) 1.73
Dominant missense mutations in ABCC9 cause Cantú syndrome. Nat Genet (2012) 1.50
Medicine. The ultimate genetic test. Science (2012) 1.41
Transgenic mouse model of ventricular preexcitation and atrioventricular reentrant tachycardia induced by an AMP-activated protein kinase loss-of-function mutation responsible for Wolff-Parkinson-White syndrome. Circulation (2004) 1.35
Strategic approaches to unraveling genetic causes of cardiovascular diseases. Circ Res (2011) 1.31
Genes and coronary artery disease: where are we? J Am Coll Cardiol (2012) 1.25
Exome sequencing identifies MRPL3 mutation in mitochondrial cardiomyopathy. Hum Mutat (2011) 1.22
Alpha-cardiac myosin heavy chain (MYH6) mutations affecting myofibril formation are associated with congenital heart defects. Hum Mol Genet (2010) 1.22
Homozygosity mapping and exome sequencing reveal GATAD1 mutation in autosomal recessive dilated cardiomyopathy. Circ Cardiovasc Genet (2011) 1.10
Recent methods for polygenic analysis of genome-wide data implicate an important effect of common variants on cardiovascular disease risk. BMC Med Genet (2011) 1.09
DNA sequencing: clinical applications of new DNA sequencing technologies. Circulation (2012) 1.03
Next steps in cardiovascular disease genomic research--sequencing, epigenetics, and transcriptomics. Clin Chem (2011) 0.95
Using pharmacogenetics in real time to guide warfarin initiation: a clinician update. Circulation (2011) 0.94
Genome sequencing. Search for pore-fection. Science (2012) 0.92
Integrating genomes. Science (2012) 0.91
Identifying genes for coronary artery disease: An idea whose time has come. Can J Cardiol (2007) 0.90
Challenges in medical applications of whole exome/genome sequencing discoveries. Trends Cardiovasc Med (2012) 0.88
Decreased left ventricular ejection fraction in transgenic mice expressing mutant cardiac troponin T-Q(92), responsible for human hypertrophic cardiomyopathy. J Mol Cell Cardiol (2000) 0.83
A customized genetic approach to the number one killer: coronary artery disease. Curr Opin Cardiol (2008) 0.82
Secrets of the human genome disclosed. Nature (2011) 0.81
Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet (2011) 13.25
Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet (2012) 12.10
Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet (2012) 7.59
A genome-wide meta-analysis identifies 22 loci associated with eight hematological parameters in the HaemGen consortium. Nat Genet (2009) 6.31
Identification of a genetic locus for familial atrial fibrillation. N Engl J Med (1997) 4.66
Common variants at 10 genomic loci influence hemoglobin A₁(C) levels via glycemic and nonglycemic pathways. Diabetes (2010) 4.07
Somatic mutations in the connexin 40 gene (GJA5) in atrial fibrillation. N Engl J Med (2006) 3.59
Tissue Doppler imaging consistently detects myocardial abnormalities in patients with hypertrophic cardiomyopathy and provides a novel means for an early diagnosis before and independently of hypertrophy. Circulation (2001) 3.33
Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy. Circulation (2001) 3.21
Design of the Coronary ARtery DIsease Genome-Wide Replication And Meta-Analysis (CARDIoGRAM) Study: A Genome-wide association meta-analysis involving more than 22 000 cases and 60 000 controls. Circ Cardiovasc Genet (2010) 3.15
Gene dosage of the common variant 9p21 predicts severity of coronary artery disease. J Am Coll Cardiol (2010) 3.07
Functional analysis of the chromosome 9p21.3 coronary artery disease risk locus. Arterioscler Thromb Vasc Biol (2009) 2.79
Rare copy number variation discovery and cross-disorder comparisons identify risk genes for ADHD. Sci Transl Med (2011) 2.29
Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circulation (2001) 2.23
MYH11 mutations result in a distinct vascular pathology driven by insulin-like growth factor 1 and angiotensin II. Hum Mol Genet (2007) 2.17
A genome-wide association study reveals variants in ARL15 that influence adiponectin levels. PLoS Genet (2009) 2.09
Disruption at the PTCHD1 Locus on Xp22.11 in Autism spectrum disorder and intellectual disability. Sci Transl Med (2010) 1.75
Novel polymorphisms in promoter region of atp binding cassette transporter gene and plasma lipids, severity, progression, and regression of coronary atherosclerosis and response to therapy. Circ Res (2001) 1.74
Aldosterone, through novel signaling proteins, is a fundamental molecular bridge between the genetic defect and the cardiac phenotype of hypertrophic cardiomyopathy. Circulation (2004) 1.72
Tissue Doppler imaging consistently detects myocardial contraction and relaxation abnormalities, irrespective of cardiac hypertrophy, in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circulation (2000) 1.72
A variant of p22(phox), involved in generation of reactive oxygen species in the vessel wall, is associated with progression of coronary atherosclerosis. Circ Res (2000) 1.66
Kinesin family member 6 variant Trp719Arg does not associate with angiographically defined coronary artery disease in the Ottawa Heart Genomics Study. J Am Coll Cardiol (2009) 1.64
Early diagnosis of acute myocardial infarction based on assay for subforms of creatine kinase-MB. Circulation (1990) 1.61
Plasma homocyst(e)ine concentration, but not MTHFR genotype, is associated with variation in carotid plaque area. Stroke (1999) 1.59
Tissue Doppler imaging predicts the development of hypertrophic cardiomyopathy in subjects with subclinical disease. Circulation (2003) 1.56
Dominant-negative effect of a mutant cardiac troponin T on cardiac structure and function in transgenic mice. J Clin Invest (1998) 1.47
Nuclear plakoglobin is essential for differentiation of cardiac progenitor cells to adipocytes in arrhythmogenic right ventricular cardiomyopathy. Circ Res (2011) 1.47
Blood pressure loci identified with a gene-centric array. Am J Hum Genet (2011) 1.44
A prospective study of genetic markers of susceptibility to infection and inflammation, and the severity, progression, and regression of coronary atherosclerosis and its response to therapy. J Mol Med (Berl) (2000) 1.42
Rare copy number variants contribute to congenital left-sided heart disease. PLoS Genet (2012) 1.35
Mammalian vestigial-like 2, a cofactor of TEF-1 and MEF2 transcription factors that promotes skeletal muscle differentiation. J Biol Chem (2002) 1.35
Transgenic mouse model of ventricular preexcitation and atrioventricular reentrant tachycardia induced by an AMP-activated protein kinase loss-of-function mutation responsible for Wolff-Parkinson-White syndrome. Circulation (2004) 1.35
A genome-wide association study for coronary artery disease identifies a novel susceptibility locus in the major histocompatibility complex. Circ Cardiovasc Genet (2012) 1.35
Prevention of cardiac hypertrophy by atorvastatin in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circ Res (2005) 1.34
Left ventricular and myocardial function in mice expressing constitutively pseudophosphorylated cardiac troponin I. Circ Res (2009) 1.33
A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary artery disease. J Clin Invest (1995) 1.32
The hippo pathway is activated and is a causal mechanism for adipogenesis in arrhythmogenic cardiomyopathy. Circ Res (2013) 1.30
Homocysteine and coronary heart disease: meta-analysis of MTHFR case-control studies, avoiding publication bias. PLoS Med (2012) 1.27
Genes and coronary artery disease: where are we? J Am Coll Cardiol (2012) 1.25
Improved prediction of cardiovascular disease based on a panel of single nucleotide polymorphisms identified through genome-wide association studies. Circ Cardiovasc Genet (2010) 1.23
Angiotensin II and stretch activate NADPH oxidase to destabilize cardiac Kv4.3 channel mRNA. Circ Res (2006) 1.20
Expression profiling of cardiac genes in human hypertrophic cardiomyopathy: insight into the pathogenesis of phenotypes. J Am Coll Cardiol (2001) 1.17
TEF-1 and MEF2 transcription factors interact to regulate muscle-specific promoters. Biochem Biophys Res Commun (2002) 1.16
Interferon-γ activates expression of p15 and p16 regardless of 9p21.3 coronary artery disease risk genotype. J Am Coll Cardiol (2012) 1.15
Role of candidate modifier genes on the phenotypic expression of hypertrophy in patients with hypertrophic cardiomyopathy. J Investig Med (1997) 1.15
Vgl-4, a novel member of the vestigial-like family of transcription cofactors, regulates alpha1-adrenergic activation of gene expression in cardiac myocytes. J Biol Chem (2004) 1.14
Genomics and cardiac arrhythmias. J Am Coll Cardiol (2005) 1.13
Candidate genetic analysis of plasma high-density lipoprotein-cholesterol and severity of coronary atherosclerosis. BMC Med Genet (2009) 1.11
Clinical and genetic association of serum paraoxonase and arylesterase activities with cardiovascular risk. Arterioscler Thromb Vasc Biol (2012) 1.10
Clinical and genetic association of serum ceruloplasmin with cardiovascular risk. Arterioscler Thromb Vasc Biol (2011) 1.10
Localization of a gene responsible for familial dilated cardiomyopathy to chromosome 1q32. Circulation (1995) 1.09
Transcription enhancer factor-1-related factor-transgenic mice develop cardiac conduction defects associated with altered connexin phosphorylation. Circulation (2004) 1.08
Gene expression changes associated with fibronectin-induced cardiac myocyte hypertrophy. Physiol Genomics (2004) 1.08
Comparative genome-wide association studies in mice and humans for trimethylamine N-oxide, a proatherogenic metabolite of choline and L-carnitine. Arterioscler Thromb Vasc Biol (2014) 1.08
Prognostic significance of beta-myosin heavy chain mutations is reflective of their hypertrophic expressivity in patients with hypertrophic cardiomyopathy. J Investig Med (1997) 1.06
Transcription cofactor Vgl-2 is required for skeletal muscle differentiation. Genesis (2004) 1.06
Angiotensin-I converting enzyme genotype DD is a risk factor for coronary artery disease. J Investig Med (1995) 1.05
Evolution of expression of cardiac phenotypes over a 4-year period in the beta-myosin heavy chain-Q403 transgenic rabbit model of human hypertrophic cardiomyopathy. J Mol Cell Cardiol (2004) 1.03
Expression of a missense mutation in the messenger RNA for beta-myosin heavy chain in myocardial tissue in hypertrophic cardiomyopathy. J Clin Invest (1992) 1.01
IRF2BP2 is a skeletal and cardiac muscle-enriched ischemia-inducible activator of VEGFA expression. FASEB J (2010) 1.00
Molecular mechanisms of cardiac myofilament activation: modulation by pH and a troponin T mutant R92Q. Basic Res Cardiol (2002) 0.98
Variants of trophic factors and expression of cardiac hypertrophy in patients with hypertrophic cardiomyopathy. J Mol Cell Cardiol (2000) 0.97
Clonal isolation of different strains of mouse mammary tumor virus-like DNA sequences from both the breast tumors and non-Hodgkin's lymphomas of individual patients diagnosed with both malignancies. Clin Cancer Res (2004) 0.96
LMO4 mRNA stability is regulated by extracellular ATP in F11 cells. Biochem Biophys Res Commun (2007) 0.96
Human polymorphism of P-selectin glycoprotein ligand 1 attributable to variable numbers of tandem decameric repeats in the mucinlike region. Blood (2001) 0.96
Circulating brain-derived neurotrophic factor concentrations and the risk of cardiovascular disease in the community. J Am Heart Assoc (2015) 0.96
A prospective study of paraoxonase gene Q/R192 polymorphism and severity, progression and regression of coronary atherosclerosis, plasma lipid levels, clinical events and response to fluvastatin. Atherosclerosis (2001) 0.95
Effects of PPARalpha, gamma and delta haplotypes on plasma levels of lipids, severity and progression of coronary atherosclerosis and response to statin therapy in the lipoprotein coronary atherosclerosis study. Pharmacogenetics (2004) 0.95
Apolipoprotein E genotypes and response of plasma lipids and progression-regression of coronary atherosclerosis to lipid-lowering drug therapy. J Am Coll Cardiol (2000) 0.95
9p21 and the genetic revolution for coronary artery disease. Clin Chem (2011) 0.94
Mouse DTEF-1 (ETFR-1, TEF-5) is a transcriptional activator in alpha 1-adrenergic agonist-stimulated cardiac myocytes. J Biol Chem (2002) 0.93
The genetics of coronary artery disease. Curr Opin Cardiol (2012) 0.92
The transcription factor GATA-2 does not associate with angiographic coronary artery disease in the Ottawa Heart Genomics and Cleveland Clinic GeneBank Studies. Hum Genet (2009) 0.92
Hypertrophic cardiomyopathy mutation is expressed in messenger RNA of skeletal as well as cardiac muscle. Circulation (1993) 0.92
Molecular genetics and pathogenesis of arrhythmogenic right ventricular cardiomyopathy: a disease of cardiac stem cells. Pediatr Cardiol (2011) 0.92
On mice, rabbits, and human heart failure. Circulation (2005) 0.92
Identification of a phosphorylation-dependent nuclear localization motif in interferon regulatory factor 2 binding protein 2. PLoS One (2011) 0.91
Differential expression of a transcription regulatory factor, the LIM domain only 4 protein Lmo4, in muscle sensory neurons. Development (2002) 0.91
Assessment of the 9p21.3 locus in severity of coronary artery disease in the presence and absence of type 2 diabetes. BMC Med Genet (2013) 0.90
Effects of SREBF-1a and SCAP polymorphisms on plasma levels of lipids, severity, progression and regression of coronary atherosclerosis and response to therapy with fluvastatin. J Mol Med (Berl) (2002) 0.90
Identifying genes for coronary artery disease: An idea whose time has come. Can J Cardiol (2007) 0.90
Induction and reversal of cardiac phenotype of human hypertrophic cardiomyopathy mutation cardiac troponin T-Q92 in switch on-switch off bigenic mice. J Am Coll Cardiol (2004) 0.89
Genomics in coronary artery disease: past, present and future. Can J Cardiol (2010) 0.88
Insulin suppresses the expression of amyloid precursor protein, presenilins, and glycogen synthase kinase-3beta in peripheral blood mononuclear cells. J Clin Endocrinol Metab (2011) 0.88
Alpha(1)-adrenergic activation of the cardiac ankyrin repeat protein gene in cardiac myocytes. Gene (2002) 0.88
The genome-wide association study--a new era for common polygenic disorders. J Cardiovasc Transl Res (2010) 0.87
Troponin I protein kinase C phosphorylation sites and ventricular function. Cardiovasc Res (2004) 0.87
RANTES/CCL5 and risk for coronary events: results from the MONICA/KORA Augsburg case-cohort, Athero-Express and CARDIoGRAM studies. PLoS One (2011) 0.87
Tail-anchored membrane protein SLMAP is a novel regulator of cardiac function at the sarcoplasmic reticulum. Am J Physiol Heart Circ Physiol (2011) 0.87
Extracellular ATP-dependent upregulation of the transcription cofactor LMO4 promotes neuron survival from hypoxia. Exp Cell Res (2007) 0.86
A common mutation in methylenetetrahydrofolate reductase gene is not a major risk of coronary artery disease or myocardial infarction. Atherosclerosis (1997) 0.85
Beta-adrenergic receptors signaling and heart failure in mice, rabbits and humans. J Mol Cell Cardiol (2006) 0.85
The LIM domain only 4 protein is a metabolic responsive inhibitor of protein tyrosine phosphatase 1B that controls hypothalamic leptin signaling. J Neurosci (2013) 0.84